linjc16/ctgov huggingface dataset:
Oral Manifestation in Patients With SARS-CoV2 Infection.

Study Overview
=================
Brief Summary
-----------------
The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a biological barometer of both viral infection and viral immunosuppression advancement .

Detailed Description
-----------------
The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection . Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Official Title
-----------------
Oral Manifestation in Patients With SARS-CoV2 Infection.

Conditions
-----------------
SARS-CoV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of SARS-CoV2 with PCR. Age range from 18-60 years old Exclusion Criteria: Pregnancy or contraceptive pills Lactation Any auto-immune disease that could affect the oral mucosa On any neoplastic therapy. Uncontrolled diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oral manifestation | describe the patient oral manifestation | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral Manifestation, SARS-CoV2, prevelance
Epidemiology of Diverticulitis in Lung Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess incidence, treatment modalities and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (LTRs) in order to establish improved treatment strategies in this high risk patient collective.

Detailed Description
-----------------
Sigmoid diverticulitis is common and potentially problematic in immunosuppressed patients. The choice between conservative and surgical treatment for uncomplicated diverticulitis remains unclear, as well as the value of the Hartmann's procedure (HP) for complicated diverticulitis. Our aim is to assess incidence, treatment options and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (LTRs) by retrospectively analysing our prospective database of around 400 lung transplant recipients transplanted between 1992 and 2013.

Official Title
-----------------
Long-term Follow-up of Lung Transplant Recipients With Diverticulitis

Conditions
-----------------
Diverticulitis, Lung Transplant Recipients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung transplant recipient Diverticulitis Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung transplant recipients with uncomplicated diverticulitis<br>Retrospective data analysis of treatment, outcome and recurrency-rate | |
| Lung transplant recipients with complicated diverticulitis<br>Retrospective data analysis of treatment, outcome and recurrency-rate | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiology of Diverticulitis in Lung Transplant Recipients | Our aim is to assess incidence, treatment options and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (LTRs) by retrospectively analysing a prospective database of around 400 LTRs transplanted between 1992 and 2013. | January 1992- December 2013 (22 years) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung transplant recipients, diverticulitis, immunosuppression
Efficacy, Safety, and Pharmacokinetics of QAW039

Study Overview
=================
Brief Summary
-----------------
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.

Official Title
-----------------
A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma

Conditions
-----------------
Persistent Asthma

Intervention / Treatment
-----------------
* Drug: QAW039 capsules once daily for 28 days
* Drug: Placebo to QAW039 capsules once daily for 28 days
* Drug: Fluticasone propionate inhaler twice daily for 28 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a medical history of mild to moderate persistent allergic asthma. Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of >17 kg/m2. Female patients must be surgically sterilized, postmenopausal or using a double-barrier method of contraception Exclusion Criteria: Women of child-bearing potential. Smokers defined as history of smoking in the previous 6 months or a smoking history of more than 10 pack years, a pack year being defined as smoking the equivalent of 20 cigarettes - a pack - every day for the period of 1 year Patients with severe persistent asthma Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>QAW039 capsules once daily for 28 days | Drug: QAW039 capsules once daily for 28 days<br> <br> |
| Experimental: 2<br>Placebo to QAW039 capsules once daily for 28 days | Drug: Placebo to QAW039 capsules once daily for 28 days<br> <br> |
| Experimental: 3<br>Fluticasone propionate inhaler twice daily for 28 days | Drug: Fluticasone propionate inhaler twice daily for 28 days<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in trough forced expiratory volume in 1 second (FEV1) compared to placebo. |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety of a 28 day administration of QAW039 compared to placebo, measured by vital signs, laboratory evaluations and electrocardiograms. |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma
Intervetional Lay Open and Curettage Versus Endoscopic (E.P.Si.T) Method in the Treatment of Sacrococcygeal Pilonidal Sinus Disease

Study Overview
=================
Brief Summary
-----------------
Aim of the work To compare lay open technique versus Endoscopic pilonidal sinus treatment as regards recurrence rate, operative data, postoperative pain, intra and postoperative complications, healing time and return to daily activity

Detailed Description
-----------------
Introduction Pilonidal sinus is a very common inflammatory disease of gluteal region (McCallum et al., 2008). Its incidence is 26/100,000 and it usually occurs in working males of age 15 to 30. The disease itself dates back to 1833 when Herbert Mayo, British Physiologist, Anatomist and Surgeon described it as a sinus containing hair follicles located in the sacrococcygeal region in a woman.

Official Title
-----------------
Lay Open and Curettage Versus Endoscopic (E.P.Si.T) Method in the Treatment of Sacrococcygeal Pilonidal Sinus Disease

Conditions
-----------------
Endoscopic Pilonidal Sinus

Intervention / Treatment
-----------------
* Procedure: Lay open and curettage
* Procedure: Endoscopic (E.P.Si.T) method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients of both genders with symptoms from sacrococcygeal pilonidal sinus were included in our study. Exclusion Criteria: Abscess formation 2. Immunodeficiency. 3. Patients with congenital asymptomatic pits. 4. Patient with psychiatric disease disabling surgical intervention. 5. Pregnant females
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lay open and curettage<br>Lay open and curettage in Pilonidal sinus | Procedure: Lay open and curettage<br>* Lay open and curettage<br>|
| Active Comparator: Endoscopic (E.P.Si.T) method<br>Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease | Procedure: Endoscopic (E.P.Si.T) method<br>* Endoscopic (E.P.Si.T) method<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence rate | recurrence rate of pilonidal sinus symptoms after healing | one year |
Transdermal Lidocaine for Pain Control During Hysterosalpingography

Study Overview
=================
Brief Summary
-----------------
the study aims to investigate the effectiveness of Transdermal lidocaine patch for Pain Control During Hysterosalpingography

Detailed Description
-----------------
hysterosalpingography can cause pain and discomfort in several ways: Use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the cannula; and injection of the dye

Official Title
-----------------
Transdermal Lidocaine for Pain Control During Hysterosalpingography: A Randomized Controlled Trial

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Drug: lidocaine patch
* Drug: Sham patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient came for Hysterosalpingography Exclusion Criteria: any patient has contraindication to Hysterosalpingography

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: double blind randomized trial
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lidocaine patch<br>5% lidocaine patch applied at 3 hours before the procedure | Drug: lidocaine patch<br>* lidocaine patch applied 3 hours before the procedure<br>* Other names: Experimental;|
| Placebo Comparator: Sham patch<br>Sham patch containing no study medication applied 3 hours before the procedure | Drug: Sham patch<br>* Sham patch applied 3 hours before the procedure<br>* Other names: Placebo Comparator;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pain score during the procedure | Assessment of pain using visual analog scale 0-10, 0 = minimum and 10 = maximum scores | 10 minutes |
The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy

Study Overview
=================
Brief Summary
-----------------
This study was designed to assess the effectiveness of epidural patient-controlled analgesia compared to intravenous patient-controlled analgesia in patients undergoing laparoscopic gastrectomy. The investigators hypothesized that epidural PCA would be more effective in pain control than IV PCA even for laparoscopic gastrectomy.

Official Title
-----------------
The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: Epidural PCA Ropivacaine
* Drug: IV PCA Fentanyl+nefopam+Ramosetron


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed adenocarcinoma in stomach Males or Females, aged≥19 years and ≤80 years Scheduled as laparoscopic gastrectomy Patient has given their written informed consent to participate in the study Exclusion Criteria: History of hypersensitivity for analgesics Recent history of narcotic analgesics Disability of central nerve system Uncontrolled co-morbidity

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epidural PCA group<br>Epidural patient-controlled analgesia group | Drug: Epidural PCA Ropivacaine<br>* Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level. Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S<br>* Other names: Epidural patient-controlled analgesia Ropivacaine;|
| Active Comparator: IV PCA group<br>Intravenous patient-controlled analgesia | Drug: IV PCA Fentanyl+nefopam+Ramosetron<br>* Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.<br>* Other names: intravenous patient-controlled analgesia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS score | pain degree was checked at every 24hours for 5days after operation | 24 hours after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participants with complication | PCA related complication | for 5days after operation | 
| Bowel motility | by counting Colomark on abdomen x-ray | for 5days after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PCA, Gastric cancer, epidural, laparoscopy
Increasing Patient Engagement in the Annual Well Visits Program

Study Overview
=================
Brief Summary
-----------------
NYU Langone Health calls patients to remind them to schedule their annual well-health appointments (including annual well visit, mammograms, etc.). The proposed study will test different iterations of the call script with the goal of increasing call completion rate and the number of scheduled appointments within an appropriate timeframe.

Official Title
-----------------
Increasing Patient Engagement in the Annual Well Visits Program at NYU Langone Health

Conditions
-----------------
Annual Visit, Well Visit

Intervention / Treatment
-----------------
* Other: Current Script
* Other: Alternate Script Iterations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Members attributed to NYU Langone Health under a shared savings arrangement who are due for preventive services and/or screenings and are eligible to be receiving a reminder call. Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Current Script Version<br>This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health. | Other: Current Script<br>* This is the version of the phone call script currently used at NYU Langone Health.<br>|
| Script Iterations<br>This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script. | Other: Alternate Script Iterations<br>* Intervention includes various iterations of the phone call script (different wording or script structure).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of scheduled annual visits |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Call completion rate | Call completion rate refers to the percentage of phone calls that successfully complete all steps of the call script. | 6 months |
Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to understand the clinical characteristics of Taiwanese eating disorders as well as establishment of the psychometric properties of eating disorder-related questionnaires (EDI and BITE).

Detailed Description
-----------------
The study subjects include three group of population: 1st group is non-clinical nursing college students (N=800); 2nd group is clinical eating disorder patients (N=600) and 3rd group is age-, sex-matched clinical non-eating disorder patients (N=600). Clinical patients are screened by eating disorder module of the SCID and are grouped into eating disorder or non-eating disorder group. After written informed consent, eating disorder patients will receive clinical assessments which included important clinical characteristics and psychopathology of eating disorders by experienced senior psychiatrists. All clinical patients are asked to complete the self-rating scales which included eating and general psychological functioning questionnaires.

Official Title
-----------------
Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population

Conditions
-----------------
Eating Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with eating disorders, patients with non-eating disorders, nursing school students Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EDI,, cross-cultural,, eating disorders,, psychometrics
Evaluation of a Touchless Vein Scanner for Venepuncture and Cannulation in Pediatric Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of the AccuVein ® AV 300 vein scanner in clinical routine in a pediatric operation room setting for a 4 weeks period. Assessment of usability, anonymous clinical register of every venepuncture(age, gender, size, weight, punction site, number of attempts, time until successful cannulation, local anaesthesia, general anaesthesia, pain scales: faces pain scale und BPS/BPOS).

Detailed Description
-----------------
For application of drugs and liquids a peripheral venous access is necessary in anaesthesiological procedures.The peripheral venepuncture is a painful procedure and induces a higher level of perioperative stress in children. The punction of peripheral veins in children can be made difficult by the often distinctive amount of subcutaneous fat or other medical conditions. The AccuVein ® AV300 vein scanner is a contactless, laser-driven device made for facilitate the search for peripheral veins up to a depth of 7mm. This could lead to a minimization of time until successful puncture and smaller number of failures.

Official Title
-----------------
Venepuncture and Vein Cannulation With Support of the AccuVein AV300 Vein Scanner in Paediatric Patients in a Pre-operation Setting

Conditions
-----------------
Venepuncture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 0 to 17 years perioperative indication for peripheral venous access regular work time of the operation room from 7 am to 4 pm Exclusion Criteria: age more than 17 years no indication for or already established venous access

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SCAN<br>Venepuncture performed with support of the AccuVein 300 vein scanner. | |
| NO_SCAN<br>Venepuncture without support of the vein scanner. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time until completion of procedure | minutes until successful puncture and cannulation of peripheral vein | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of attempts until completion of procedure | number of attempts until successful puncture and cannulation of peripheral vein | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric anesthesia, venepuncture, peripheral venous access